8-K: Vivos Therapeutics Reports 78% Q3 Revenue Growth

Vivos Therapeutics announced significant revenue growth in Q3 2025, driven by its strategic pivot to medical sleep practices and the first full quarter of Sleep Center of Nevada operations.

Summary

• Revenue for the third quarter of 2025 was $6.8 million, representing a 78% sequential quarter-over-quarter increase and a 76% year-over-year increase compared to $3.9 million in Q3 2024.
• Revenue for the nine months ended September 30, 2025, was $13.6 million, up from $11.3 million for the comparable period in 2024.
• The June 2025 acquisition of The Sleep Center of Nevada (SCN) contributed $2.2 million in diagnostic sleep testing revenue and $1.3 million in new treatment center revenue during Q3 2025.
• Gross profit for Q3 2025 was $3.9 million, compared to $2.3 million in Q3 2024.
• Gross margin declined to 58% in Q3 2025 from 60% in Q3 2024, and to 55% for the nine months ended September 30, 2025, from 61% in the same period in 2024.
• Operating expenses for Q3 2025 increased by 74% to $8.7 million, compared to $5.0 million in Q3 2024, primarily due to increased headcount and non-cash depreciation/amortization from the SCN acquisition.
• The operating loss for Q3 2025 increased to $4.7 million, compared to $2.6 million in Q3 2024.
• Net loss for Q3 2025 was $5.4 million, compared to $2.6 million in Q3 2024, resulting in a net loss per share of $(0.49) versus $(0.40) in Q3 2024.
• Cash and cash equivalents were $3.1 million as of September 30, 2025, down from $6.3 million as of December 31, 2024.
• Stockholders' equity was $2.5 million as of September 30, 2025, down from $8.0 million as of December 31, 2024.
• The company launched an updated sleep practice affiliation model, entering into a management agreement with MISleep Solutions LLC in Auburn Hills, Michigan, with patient services anticipated to begin in early December.

Sentiment

Score: 7

Explanation: The significant revenue growth and positive impact of the strategic pivot are strong positives. However, the substantial increase in operating loss, net loss, and cash burn, along with declining cash reserves and equity, temper the overall sentiment. The company is in an investment phase with clear strategic direction, but financial health metrics show increased risk.

Positives

• Achieved significant sequential revenue growth of 78% quarter-over-quarter in Q3 2025, reaching $6.8 million.
• Reported a 76% year-over-year revenue increase in Q3 2025, demonstrating strong market penetration.
• The Sleep Center of Nevada (SCN) acquisition successfully contributed $2.2 million in diagnostic sleep testing revenue and $1.3 million in new treatment center revenue in its first full quarter of operations.
• The strategic pivot towards direct medical sleep practice affiliations and acquisitions is showing early benefits in both revenue and gross profit.
• Experienced overwhelming and growing patient demand in the Las Vegas area, with SCN booking sleep testing appointments into the latter part of February 2026.
• Actively pursuing expansion of the new model into additional major markets beyond Las Vegas through contractual alliances or acquisitions.
• Successfully launched a new sleep practice affiliation model in Auburn Hills, Michigan, with Vivos holding a supermajority equity stake in the management services company.

Negatives

• Gross margin declined to 58% in Q3 2025 from 60% in Q3 2024, and to 55% for the nine months ended September 30, 2025, from 61% in the same period in 2024, attributed to pricing discounts, shifts in product/service mix, and the new sales model.
• Operating expenses increased substantially by 74% to $8.7 million in Q3 2025, primarily due to increased headcount and non-cash depreciation/amortization related to the SCN acquisition.
• Operating loss widened to $4.7 million in Q3 2025 from $2.6 million in Q3 2024.
• Net loss increased to $5.4 million in Q3 2025 from $2.6 million in Q3 2024.
• Cash and cash equivalents decreased significantly to $3.1 million as of September 30, 2025, from $6.3 million at December 31, 2024.
• Stockholders' equity decreased to $2.5 million as of September 30, 2025, from $8.0 million at December 31, 2024.
• Higher levels of expenses are expected to continue near term as the company optimizes SCN's operations, adds staff, and credentials more providers.

Risks

• The risk that Vivos may be unable to continue to integrate SCN's business into its own or otherwise implement sales, marketing, and other strategies that effectively increase revenues.
• The risk that some patients may not achieve the desired results from using Vivos products.
• Risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea diagnosis and treatment sector.
• The risk that Vivos may be unable to secure additional financing to acquire additional sleep centers/practices on reasonable terms when needed, if at all, or maintain its Nasdaq listing.
• Market and other conditions that could impact Vivos' business or ability to obtain financing.

Future Outlook

Management anticipates continued higher expenses near term as they optimize SCN operations, drive further revenue, add staff, and credential more providers. During 2026, the company expects to add new sleep optimization teams, which are projected to reduce cash burn and create potential for profitable operations. Vivos also plans to expand revenue opportunities through additional acquisitions or contractual alliances in key target markets.

Management Comments

• "Our third quarter sequential revenue was up 78%, while same period year-over-year revenue increased 76%. This outstanding quarterly revenue increase represents exactly what we anticipated when we announced and executed our strategic pivot away from our historical reliance on a dental industry distribution channel and toward a direct affiliation with, or acquisition of, medical sleep practices and testing centers." Kirk Huntsman, CEO.
• "Even at this early stage, we are seeing the benefits of our strategic pivot in both revenue and gross profit, and these results provide us with confidence in where our new strategic affiliation and acquisition model will take us." Kirk Huntsman, CEO.
• "We are currently booking SCN patients for sleep testing out into the latter part of February 2026 as we work to rapidly add additional facilities, staff and providers." Kirk Huntsman, CEO.
• "The launch of our new model at SCN required key investments in people and infrastructure in advance of full-capacity revenue generating operations. This resulted in some higher levels of expenses during the quarter." Bradford Amman, CFO.
• "We expect this to continue near term as we seek to optimize SCNs operations by driving revenue further, adding staff, and eventually getting more providers credentialed with insurance payors." Bradford Amman, CFO.
• "During 2026, we expect to continue to add new sleep optimization teams, which we believe will eventually result in a reduction in cash burn and create the potential for profitable operations." Bradford Amman, CFO.

Industry Context

Vivos Therapeutics operates in the medical technology and healthcare services sector, specifically targeting sleep-related breathing disorders like obstructive sleep apnea (OSA). The company's strategic pivot towards direct medical sleep practices and acquisitions aligns with a broader trend in healthcare to integrate specialized services and capture more direct patient engagement, moving away from reliance on traditional distribution channels. The focus on non-surgical, non-invasive, and non-pharmaceutical solutions for OSA positions Vivos as an innovator in a market where 90% of over 1 billion affected individuals remain undiagnosed, and legacy treatments like CPAP often fail to address root causes.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders face potential for increased value from strategic growth and revenue ramp-up, but also increased risk due to higher losses, cash burn, and the potential need for future financing. There has been significant dilution with weighted average shares outstanding increasing from 6,615,320 in Q3 2024 to 10,963,590 in Q3 2025.
• Employees will see increased headcount due to the SCN acquisition and plans to add more staff and providers.
• Customers/Patients will benefit from expanded access to Vivos' diagnostic and treatment options through the SCN acquisition and new affiliation model, with high demand noted.
• Creditors are impacted by increased debt levels, which rose to approximately $8.7 million as of September 30, 2025.

Next Steps

• Optimize SCN's operations by driving revenue further, adding staff, and credentialing more providers.
• Actively look to extend the new model into additional major markets beyond Las Vegas through contractual alliances or acquisitions.
• Add new sleep optimization teams during 2026 to reduce cash burn and create potential for profitable operations.
• Explore similar affiliation arrangements in other major markets across the country.
• File the Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2025, with the Securities and Exchange Commission (SEC).

Key Dates

Recommendation

While Vivos Therapeutics demonstrated impressive revenue growth (78% sequential, 76% year-over-year) driven by its strategic pivot and the SCN acquisition, the significant increase in operating expenses, net loss, and cash burn raises concerns about short-term profitability and liquidity. Cash and stockholders' equity have substantially declined, and debt has increased. The strategic direction is promising, with strong patient demand and expansion plans, but the company is in a high-investment phase with explicit risks regarding future financing. A 'hold' recommendation is appropriate as investors should monitor the company's ability to reduce cash burn, achieve profitability in 2026, and secure necessary financing without excessive dilution, before considering further investment.

Keywords

Vivos Therapeutics, VVOS, Sleep Apnea, OSA, Medical Device, Healthcare Services, Financial Results, Q3 2025, Revenue Growth, Sleep Center of Nevada, SCN Acquisition, Strategic Pivot, Obstructive Sleep Apnea, Medical Sleep Practices, Diagnostic Procedures, Treatment Methods, NASDAQ